Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Pharm ; 580: 119229, 2020 Apr 30.
Article in English | MEDLINE | ID: mdl-32184178

ABSTRACT

The study aims to assess the ultrasound-assisted econazole nitrate (EN) permeation from topically applied formulations with potential for treating Raynaud's phenomenon. Optimization of ultrasound parameters such as the distance of the horn, application time and amplitude were performed. In vitro percutaneous absorption studies were performed using econazole formulations (F2_HPMC dispersion, F4_Lipoderm® Activemax™ Cream) across the ultrasound-treated porcine skin and were compared with the control group (skin samples without ultrasound). Histology and ATR-FTIR studies were performed on treated skin samples. A constant frequency (20 kHz) ultrasound application with 40% amplitude, 0.5 cm distance between ultrasound horn and the skin surface for 2 min was optimized. The permeation of EN was found to be higher from ultrasound-treated skin samples than the control group. Drug permeation from F2_HPMC dispersion was found to be higher as compared to the other formulations and the marketed EN cream. Histological evaluation confirmed that F2_HPMC dispersion showed no signs of toxicity. ATR-FTIR studies revealed a slight increase in the CH2 stretching vibrations (~2920 cm-1 and 2850 cm-1) in ultrasound-treated skin samples as compared with the control. In conclusion, the ultrasound-assisted transdermal delivery of F2_HPMC dispersion could be further studied as a new therapy for Raynaud's phenomenon.


Subject(s)
Econazole/administration & dosage , Raynaud Disease/drug therapy , Administration, Cutaneous , Animals , Antifungal Agents/administration & dosage , Chemistry, Pharmaceutical/methods , Permeability , Skin/metabolism , Skin Absorption/physiology , Swine
2.
Curr Pharm Des ; 25(4): 413-423, 2019.
Article in English | MEDLINE | ID: mdl-30747058

ABSTRACT

Low frequency ultrasound-assisted drug delivery has been widely investigated as a non-invasive method to enhance the transdermal penetration of drugs. Using this technique, a brief application of ultrasound is used to permeabilize skin for a prolonged time. In this review, an overview on ultrasound is detailed to help explain the parameters that could be modulated to obtain the desired ultrasound parameters for enhanced transdermal drug delivery. The mechanisms of enhancement and the latest developments in the area of ultrasound-assisted transdermal drug delivery are discussed. Special emphasis is placed on the effects of ultrasound when used in combination with microneedles, electroporation and iontophoresis, and penetration enhancers. Further, this review summarizes the effect of ultrasound on skin integrity and the regulatory requirements for commercialization of the ultrasound based transdermal delivery instruments.


Subject(s)
Drug Delivery Systems , Iontophoresis , Skin Absorption , Ultrasonics , Administration, Cutaneous , Animals , Humans , Skin
3.
Pharm Dev Technol ; 24(6): 689-699, 2019 Jul.
Article in English | MEDLINE | ID: mdl-30712434

ABSTRACT

The purpose of this work was to design and characterize a topical formulation of econazole nitrate (EN) with potential for treating Raynaud's phenomenon (RP). Four topical dosage forms (F1_topical solution, F2_HPMC or hydroxypropyl methylcellulose dispersion, F3_VersaBase® cream, and F4_Lipoderm® Activemax™ Cream) containing 3% w/w EN were prepared and characterized for drug content, pH, viscosity, spreadability, drug crystallinity, stability, and in vitro permeation using Franz cells across pig ear skin, and results were compared to the 1% marketed EN cream. All four formulations had acceptable physical and visual characteristics required for topical application, with 3% w/w EN. The order of amount of drug permeated from highest to lowest was F2 (10.27%) > F4 (2.47%) > F1 (2.28%) > F3 (1.47%) > marketed formulation (0.22%). Formulation F2 showed better penetration of the drug into the stratum corneum, epidermis, and dermis layers. The drug concentration in the stratum corneum and epidermis was approximately 10-20 times higher with F2 compared to the marketed formulation. All formulations were found to be stable for up to 6 months. All four EN formulations were found to be better than the 1% marketed cream. Formulation F2_HPMC dispersion could be further explored as a treatment option for RP.


Subject(s)
14-alpha Demethylase Inhibitors/administration & dosage , Antifungal Agents/administration & dosage , Econazole/administration & dosage , Pharmaceutical Vehicles/chemistry , Raynaud Disease/drug therapy , 14-alpha Demethylase Inhibitors/pharmacokinetics , Administration, Topical , Animals , Antifungal Agents/pharmacokinetics , Crystallization , Drug Compounding/methods , Econazole/pharmacokinetics , Humans , Hypromellose Derivatives/chemistry , Raynaud Disease/metabolism , Skin Absorption , Swine
4.
Int J Pharm ; 545(1-2): 357-365, 2018 Jul 10.
Article in English | MEDLINE | ID: mdl-29747001

ABSTRACT

This project aims to study the nature of interaction and orientation of selected drugs such as dexamethorphan HBr (DXM), diphenhydramine HCl (DPH), and lidocaine HCl (LDC) inclusion complexes with hydroxyl-propyl ß-cyclodextrin (HP-ß-CD) using 1HNMR spectroscopy, 2D-NMR ROESY and molecular-modeling techniques. Freeze-drying technique was used to formulate the inclusion complexes between DXM, DPH and LDC with HP-ß-CD (1:1 M ratio) in solid state. Inclusion complex formation was initially characterized by Fourier transform-infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC), X-ray diffraction (XRD) and scanning electron microscopy (SEM) techniques. Further characterization of inclusion complexes to determine the interaction of DXM, DPH and LDC with HP-ß-CD was performed using the 1HNMR spectroscopy, 2D-NMR ROESY and molecular modeling techniques. Inclusion complexes of DXM, DPH and LDC with HP-ß-CD were successfully prepared using the freeze-drying technique. Preliminary studies with FT-IR, DSC, XRD and SEM indicated the formation of inclusion complexes of DXM, DPH and LDC with HP-ß-CD at 1:1 M ratio. 1HNMR study showed a change in proton chemical shift upon complexation. 2D-NMR ROESY (two-dimensional) spectroscopy gave an insight into the spatial arrangement between the host and guest atoms. 2D-ROESY experiments further predicted the direction of orientation of guest molecules, indicating the probability that amino moieties of DXM, DPH and LDC are inside the hydrophobic HP-ß-CD cavity. Cross-peaks of inclusion complexes demonstrated intermolecular nuclear Overhauser effects (NOE) between the amino protons in DXM, DPH and LDC and H-atoms of HP-ß-CD. Molecular modeling studies further confirmed the NMR data, providing a structural basis of the individual complex formations. Microsecond time-level molecular dynamics and metadynamics simulations indicate much stronger binding of DXM to HP-ß-CD and more dynamic behavior for DPH and LDC. In particular, LDC can exhibit multiple binding modes, and even spent some time (∼1-2%) out of the carrier, proving the dynamic nature of the complex. To conclude, 2D-NMR and molecular dynamic simulations elucidate the formation of inclusion complexes and intermolecular interactions of DXM, DPH and LDC with HP-ß-CD.


Subject(s)
2-Hydroxypropyl-beta-cyclodextrin/chemistry , Excipients/chemistry , Molecular Docking Simulation , Molecular Dynamics Simulation , Pharmaceutical Preparations/chemistry , Proton Magnetic Resonance Spectroscopy , Technology, Pharmaceutical/methods , Calorimetry, Differential Scanning , Crystallography, X-Ray , Dextromethorphan/chemistry , Diphenhydramine/chemistry , Drug Compounding , Freeze Drying , Lidocaine/chemistry , Microscopy, Electron, Scanning , Spectroscopy, Fourier Transform Infrared
5.
Article in English | MEDLINE | ID: mdl-24447050

ABSTRACT

Murraya koenigii (Curry leaves) has been widely used in Asian countries for the treatment of some ailments such as diabetes and hypertension. In the present study, leaves of Murraya koenigii were extracted with ethanol and evaluated for anti-inflammatory activity in rats using carrageenan induced paw edema method. Ethanolic extract showed a potent anti-inflammatory activity at third hour after carrageenan administration when compared with the standard drug, Diclofenac. The percent inhibition of paw volume was found to be 84.75% for 50 mg/kg of extract whereas it was found to be 80.86% for 50 mg/kg extract in combination with Diclofenac 10 mg/kg. Thus, the present study suggests that the combination therapy potentiates the anti-inflammatory effect of diclofenac and may help in reducing the dose of the synthetic drug. Some relevant patents are also outlined in this article.


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Diclofenac/administration & dosage , Edema/drug therapy , Plant Extracts/administration & dosage , Rutaceae/immunology , Animals , Carrageenan/administration & dosage , Drug Synergism , Drug Therapy, Combination , Edema/chemically induced , Female , Humans , Male , Plant Leaves , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...